Endralazine in patients with severe hypertension and renal insufficiency.
作者信息
Higgs E R, Harrison P R, Banks R A, Kingswood J C, Mackenzie J C
出版信息
Postgrad Med J. 1982 Dec;58(686):767-70. doi: 10.1136/pgmj.58.686.767.
Abstract
Endralazine, a new peripheral vasodilator, was given in conjunction with a beta-blocker to 21 patients with hypertension and chronic renal failure. All subjects were either poorly controlled on their previous antihypertensive regime or were experiencing unacceptable adverse effects from drugs. After 4 weeks blood pressure was reduced in all patients and symptomatic side effects were few. Two patients became anti-nuclear factor (ANF) positive in weak titre but without evidence of the lupus syndrome.
摘要
相似文献
1
Endralazine in patients with severe hypertension and renal insufficiency.
Postgrad Med J. 1982 Dec;58(686):767-70. doi: 10.1136/pgmj.58.686.767.
2
Long-term effects of endralazine (BQ-22-708) in patients with renal impairment and hypertension.
Postgrad Med J. 1983;59 Suppl 3:173-6.
3
Endralazine in treatment of hypertension in children with renal disease.
Lancet. 1983 Sep 10;2(8350):635. doi: 10.1016/s0140-6736(83)90727-4.
4
Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine.
J Hypertens Suppl. 1984 Dec;2(3):S551-4.
5
Endralazine, a new peripheral vasodilator--a randomized cross-over trial against dihydralazine.
J Cardiovasc Pharmacol. 1982 Jul-Aug;4(4):562-6. doi: 10.1097/00005344-198207000-00006.
6
Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.恩屈嗪，一种新型外周血管扩张剂。三年期间安全性和有效性评估。
Eur J Clin Pharmacol. 1983;24(3):301-5. doi: 10.1007/BF00610045.
7
Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension.
Clin Exp Hypertens A. 1982;4(8):1409-18. doi: 10.3109/10641968209060798.
8
[Antihypertensive pharmacotherapy with the vasodilators captopril and endralazine].[使用血管扩张剂卡托普利和恩屈嗪进行抗高血压药物治疗]
Schweiz Med Wochenschr. 1985 Jul 9;115(27-28):939-44.
9
Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
Curr Med Res Opin. 1986;10(3):150-8. doi: 10.1185/03007998609110434.
10
[Management of treatment-resistant hypertension: comparison of the antihypertensive effect of endralazine and minoxidil (author's transl)].
Dtsch Med Wochenschr. 1981 Sep 11;106(37):1176-81. doi: 10.1055/s-2008-1070477.
引用本文的文献
1
Evaluation of once daily endralazine in hypertension.每日一次服用恩屈嗪治疗高血压的疗效评估。
Eur J Clin Pharmacol. 1986;30(5):553-7. doi: 10.1007/BF00542414.
本文引用的文献
1
The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function.治疗对与高血压相关的血管病变的影响，尤其侧重于肾功能。
Am J Med. 1958 Feb;24(2):177-92. doi: 10.1016/0002-9343(58)90306-1.
2
Hydrallazine in hypertension: is there a safe dose?肼屈嗪治疗高血压：是否存在安全剂量？
Br Med J. 1980 Aug 2;281(6236):353-4. doi: 10.1136/bmj.281.6236.353.
3
An improved and simplified method of detecting the acetylator phenotype.一种检测乙酰化酶表型的改良简化方法。
J Med Genet. 1969 Dec;6(4):405-7. doi: 10.1136/jmg.6.4.405.
4
5
Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.肼屈嗪的迟发性毒性类似于系统性红斑狼疮或类风湿关节炎。
Am J Med. 1973 Jan;54(1):58-72. doi: 10.1016/0002-9343(73)90084-3.
Zotero 插件